Table 5 Summary of the pharmacokinetic parameters of tazarotenic acid following single-dose oral administration of Tazarotene on day 0 and at 12 weeks
From: A phase 1 study of tazarotene in adults with advanced cancer
Dose taken (mg) | Cmax day 0 (ng ml−1) | T max day 0 (h) | AUC0–inf day 0 (ng h ml−1) | T 1/2 day 0 (h) | Cmax week 12 (ng ml−1) |
|---|---|---|---|---|---|
1.4 | 40.8±18.3 | 3.2±3.5 | 195±38 | 5.62 ± 0.86 | 29.6 |
(N=6) | (20.4, 41.7, 66.3) | (1, 1, 9) | (159, 188, 243) | (4.62, 5.65, 6.78) | (N=6) |
2.1 | 68.8±27.8 | 3.6±3.3 | 279±64 | 8.36±3.59 | 41.9 |
(N=5) | (35.2, 73.2, 107) | (1, 3, 9) | (204, 308, 353) | (5.35, 8.14, 14.3) | (N=3) |
2.8 | 70.8±28.1 | 2.7±1.5 | 394±60 | 7.96±2.87 | 89.4 |
(N=3) | (45.4, 65.9, 101) | (1, 3, 4) | (328, 412, 443) | (4.81, 8.67, 10.4) | (N=1) |
4.2 | 72.9±2.1 | 3.5±3.5 | 359±1 | 4.05±0.36 | 97.8 |
(N=2) | (71.4, 72.9, 74.3) | (1, 3.5, 6) | (358, 359, 360) | (3.79, 4.05, 4.30) | (N=1) |
8.4 | 126±96 | 2.5±0.7 | 614±3 | 14.2±9.6 | — |
(N=2) | (57.8, 126, 194) | (2, 2.5, 3) | (612, 614, 616) | (7.44, 14.2, 21.0) | |
16.8 | 377±112 | 3.0±1.0 | 1751±358 | 15.4±14.3 | 325 |
(N=3) | (306, 318, 506) | (2, 3, 4) | (1341, 1915, 1998) | (1.25, 15.0, 29.9) | (N=3) |
25.2 | 561±236 | 2.1±1.1 | 2394±841 | 3.33±2.56 | 367 |
(N=7) | (191, 559, 859) | (1, 2, 4) | (1540, 2287, 3677) | (1.32, 2.35, 8.53) | (N=1) |
33.6 | 903±267 | 1.5±0.6 | 3467±707 | 8.01±6.51 | 829 |
(N=4) | (680, 823, 1286) | (1, 1.5, 2) | (2809, 3425, 4208) | (1.20, 7.90, 15.1) | (N=1) |
